[Different therapies in the treatment of obesity in hypertensive patients].
OBJECTIVE
To evaluate the efficacy and tolerability of different therapies associated with diet in the treatment of hypertensive obese patients.


METHODS
In a clinical study we randomly evaluated 39 hypertensive obese patients (body mass index (BMI) > or = 30 kg/m2). After 45 days of diet the patients were again randomly distributed in 3 groups and received in double blind way: group 1-hypocaloric diet+placebo; group 2-hypocaloric diet+dexfenfluramine; group 3-hypocaloric diet+spiruline+fucus+gelatin. We followed their progress during 12 weeks under medication and further 24 weeks without. We evaluated the groups comparing: weight, BMI, blood pressure and side-effects.


RESULTS
Twenty seven patients completed the observation. In those patients from groups 1 and 3 no changes in any of parameters were observed. In group 2 we observed a clear loss of weight (-3.8 Kg) and a fall in BMI. Blood Pressure changes were only observed in group 2 (-9.6%). The only patients to maintain weight loss after the termination of use of medicines were those from group 2. We did not observe any side-effects.


CONCLUSIONS
In hypertensive obese patients, when isolated diet is not enough to control weight loss, dexfenfluramine could be useful in association with a controlled diet. The drug assists in weight loss, does not promote side-effects and does not interfere in the treatment of blood pressure.
Monego
E T
ET
Faculdades de Medicina, Universidade Federal de Goiás, Goiânia.
Peixoto
M do R
Mdo R
Jardim
P C
PC
Sousa
A L
AL
Braga
V L
VL
Moura
M F
MF
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D018752:Diet, Fat-Restricted; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D005277:Fenfluramine / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D016896:Treatment Outcome
D005277:Fenfluramine